In today’s fast-changing world, the types of medicines being developed, the way technology contributes to health, and how the value of health care is calculated, are all undergoing a metamorphosis. A wave of cell and gene therapies are bending the definition of what constitutes a drug, both clinically, and in terms of expectations of outcomes, duration of treatment and costs. Global health is poised to meet a series of key turning points, and changes seen in 2018 will mark the key inflections that drive the outlook for the next five years and beyond.
These are examples of key observations, as captured in the March 13, 2018 research report, titled: “2018 and Beyond: Outlook and Turning Points,” of the IQVIA Institute (previously IMS Institute). Arising out of these, the report envisages the following key impacts on the pharma industry in the next five years – from 2018 to 2022:
- Patent expiry impact will be 37 percent larger than the prior five years, including both small molecule and biologics.
- New medicines’ growth will be slower in 2018 – 2022 than the period from 2013 -2017.
- Net price levels for branded drugs will rise modestly in the United States at 2–5% per year but will fall in other developed markets.
- Volume for existing branded and generic medicines will remain slow, with the ongoing shifts towards newer medicines over time.
- To increase access to medicinesGovernment and other payers to focus on addressing outstanding healthcare disparities or to invest in approaches to address system inefficiencies.
Such a situation, would obviously impede performance and productivity of many pharma players – both research-based and also the generic ones, across the world, including India.…continue reading
No comments:
Post a Comment